Realistically...the company has little chance of being able to raise any funding, so there is likely to be a sale or simply a transfer of IP to Hepalink/ORI
Even if the secondary endpoints are exceeded it is back to phase 2 and there's no cash.
Yes it’s too bad it wasn’t a success for primary endpoints. The stock is trying to recover though after a terrible drop to .25 cents from 1.66 sitting around .60 cents currently.
News 
Market Data 
Discover 
